Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer

Video

Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

More research needs to be conducted to understand the optimal use of neoadjuvant therapy, von Minckwitz explains. Biomarkers have been developed in order to determine response to treatment, as well as serve as predictive markers of pathologic complete response rates and poor predictive markers of outcomes.

Additionally, researchers can develop findings from a correlative marker in the neoadjuvant setting that can be then confirmed to the adjuvant setting.

<<<

View more from the 33rd Annual Miami Breast Cancer Conference

Related Videos
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.